{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:21:42Z","timestamp":1792408902981,"version":"4.4.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. Resistance to EGFR inhibitors is frequently associated with enhanced vascular endothelial growth factor (VEGF) levels. This multicenter, retrospective study aimed to evaluate the efficacy of the combination treatment with apatinib and osimertinib in 39 patients with EGFR-mutant non-small cell lung carcinoma (NSCLC) who developed osimertinib resistance. The patients received the combination of oral apatinib 250 mg qd and osimertinib 80 mg qd. The efficacy was evaluated after the first month then every 2 months thereafter. The primary endpoint was progression-free survival (PFS). The overall response rate (ORR) and the disease control rate (DCR) of the combination of apatinib and osimertinib was 12.8% (5\/39) and 79.5% (31\/39), respectively. The median PFS was 4 months [95% confidence interval (CI): 3.5\u20134.5 months]. Fourteen patients were administered with at least 6 months of combination therapy, and 11 of them remained on treatment programs. The 6-month PFS rate was 38%. Nine patients underwent biopsies after failing osimertinib treatment, and five of six patients with TP53 mutations had PFS of less than 3 months. The spectrum of resistance to osimertinib mechanisms included c-mesenchymal-epithelial transition factor (c-Met) amplification, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gain-of-function mutation, phosphatase and tensin homolog (PTEN) loss-of-function mutation, Erb-B2 receptor tyrosine kinase 2 (ERBB2) amplification, and insulin-like growth factor 1 receptor (IGF1R) mutation. The most common adverse events were hypertension (30.7%, 12\/39), diarrhea (15.4%, 6\/39), and proteinuria (12.8%, 5\/39). The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance.<\/jats:p>","DOI":"10.3389\/fmolb.2021.639892","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T04:19:43Z","timestamp":1620188383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma\u2014A Retrospective Analysis of a Multicenter Clinical Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Xue","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglei","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2011.03.012","article-title":"Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.","volume":"131","author":"Larsen","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.ccr-18-1542","article-title":"Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC.","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejca.2017.07.037","article-title":"Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.","volume":"84","author":"Li","year":"2017","journal-title":"Eur. J. Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.jtho.2018.06.005","article-title":"Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.","volume":"13","author":"Lin","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.21037\/tcr.2019.09.35","article-title":"Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.","volume":"8","author":"Liu","year":"2019","journal-title":"Trans Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.1158\/0008-5472.can-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.ccr-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2016.05.015","article-title":"High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.","volume":"98","author":"Ou","year":"2016","journal-title":"Lung Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","article-title":"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.","volume":"26","author":"Planchard","year":"2015","journal-title":"Ann. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"i28","DOI":"10.1093\/annonc\/mdx705","article-title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.","volume":"29","author":"Ricordel","year":"2018","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/s1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance.","volume":"12","author":"Wang","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.2147\/ott.s142686","article-title":"Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study.","volume":"10","author":"Xu","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40880-019-0414-4","article-title":"The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2019.10.021","article-title":"Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.","volume":"141","author":"Zhao","year":"2020","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.jtho.2019.04.020","article-title":"Durable clinical response of lung adenocarcinoma harboring EGFR 19Del\/T790M\/in trans-C797S to combination therapy of first- and third-generation EGFR tyrosine kinase inhibitors.","volume":"14","author":"Zhou","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","article-title":"The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma.","volume":"26","author":"Zhuo","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.639892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T04:19:45Z","timestamp":1620188385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.639892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":20,"alternative-id":["10.3389\/fmolb.2021.639892"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.639892","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"article-number":"639892"}}